Product Description
Satralizumab (Enspryng®), a humanized anti-interleukin-6 (IL-6) receptor monoclonal recycling antibody, has been developed by Chugai Pharmaceutical and Roche for the treatment of neuromyelitis optica spectrum disorder (NMOSD). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32797372/)
Mechanisms of Action: IL6 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Malaysia | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United States
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, France, Germany, Ghana, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Malaysia, Netherlands, Poland, Portugal, Puerto Rico, Romania, Russia, Singapore, South Korea, Spain, Taiwan, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 26
Highest Development Phases
Phase 3: Encephalitis|Epilepsies, Partial|Graves Disease|Graves Ophthalmopathy|Myasthenia Gravis|Neuromyelitis Optica|Other|Thyroid Eye Disease|Thyroiditis, Autoimmune
Phase 2: Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Muscular Dystrophy, Duchenne
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| WN41733 | P3 |
Unknown Status |
Neuromyelitis Optica |
2029-02-28 |
|
| jRCT2021220005 | P3 |
Recruiting |
Other |
2028-04-30 |
|
| WN43194 | P3 |
Unknown Status |
Other |
2027-12-27 |
|
| WN43174 | P3 |
Unknown Status |
Encephalitis |
2027-12-07 |